Correlation of Radiographic Progression with the Cumulative Activity of Synovitis Estimated by Power Doppler Ultrasound in Rheumatoid Arthritis: Difference Between Patients Treated with Methotrexate and Those Treated with Biological Agents
Identifieur interne : 003398 ( Main/Exploration ); précédent : 003397; suivant : 003399Correlation of Radiographic Progression with the Cumulative Activity of Synovitis Estimated by Power Doppler Ultrasound in Rheumatoid Arthritis: Difference Between Patients Treated with Methotrexate and Those Treated with Biological Agents
Auteurs : Kei Ikeda [Japon] ; Daiki Nakagomi [Japon] ; Yoshie Sanayama [Japon] ; Mieko Yamagata [Japon] ; Ayako Okubo [Japon] ; Taro Iwamoto [Japon] ; Hirotoshi Kawashima [Japon] ; Kentaro Takahashi [Japon] ; Hiroshi Nakajima [Japon]Source :
- Journal of rheumatology [ 0315-162X ] ; 2013.
Descripteurs français
- KwdFr :
- Adalimumab, Adulte, Adulte d'âge moyen, Anticorps monoclonaux (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Antirhumatismaux (usage thérapeutique), Arthrographie (), Biais de l'observateur, Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs), Femelle, Humains, Immunoglobuline G (usage thérapeutique), Infliximab, Mâle, Méthotrexate (usage thérapeutique), Polyarthrite rhumatoïde (imagerie diagnostique), Polyarthrite rhumatoïde (traitement médicamenteux), Récepteurs aux facteurs de nécrose tumorale (usage thérapeutique), Sensibilité et spécificité, Sujet âgé, Synovite (imagerie diagnostique), Synovite (traitement médicamenteux), Échographie-doppler (), Étanercept, Études prospectives, Évolution de la maladie.
- MESH :
- antagonistes et inhibiteurs : Facteur de nécrose tumorale alpha.
- imagerie diagnostique : Polyarthrite rhumatoïde, Synovite.
- traitement médicamenteux : Polyarthrite rhumatoïde, Synovite.
- usage thérapeutique : Anticorps monoclonaux, Anticorps monoclonaux humanisés, Antirhumatismaux, Immunoglobuline G, Méthotrexate, Récepteurs aux facteurs de nécrose tumorale.
- Pascal (Inist)
- Adalimumab, Adulte, Adulte d'âge moyen, Arthrographie, Biais de l'observateur, Femelle, Humains, Infliximab, Mâle, Polyarthrite rhumatoïde, Radiographie, Evolution, Pronostic, Sensibilité et spécificité, Sujet âgé, Synovite, Dopplérométrie, Ultrason, Homme, Traitement, Méthotrexate, Agent biologique, Echographie, Rhumatologie, Chronique, Antirhumatismal, Anticancéreux, Échographie-doppler, Étanercept, Études prospectives, Évolution de la maladie.
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adalimumab, Adult, Aged, Antibodies, Monoclonal (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antineoplastic agent, Antirheumatic Agents (therapeutic use), Antirheumatic agent, Arthritis, Rheumatoid (diagnostic imaging), Arthritis, Rheumatoid (drug therapy), Arthrography (methods), Arthrography (statistics & numerical data), Biological agent, Chronic, Disease Progression, Doppler ultrasound study, Echography, Etanercept, Evolution, Female, Human, Humans, Immunoglobulin G (therapeutic use), Infliximab, Male, Methotrexate, Methotrexate (therapeutic use), Middle Aged, Observer Variation, Prognosis, Prospective Studies, Radiography, Receptors, Tumor Necrosis Factor (therapeutic use), Rheumatoid arthritis, Rheumatology, Sensitivity and Specificity, Synovitis, Synovitis (diagnostic imaging), Synovitis (drug therapy), Treatment, Tumor Necrosis Factor-alpha (antagonists & inhibitors), Ultrasonography, Doppler (methods), Ultrasonography, Doppler (statistics & numerical data), Ultrasound.
- MESH :
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Immunoglobulin G, Methotrexate, Receptors, Tumor Necrosis Factor.
- chemical : Adalimumab, Etanercept, Infliximab.
- diagnostic imaging : Arthritis, Rheumatoid, Synovitis.
- drug therapy : Arthritis, Rheumatoid, Synovitis.
- methods : Arthrography, Ultrasonography, Doppler.
- statistics & numerical data : Arthrography, Ultrasonography, Doppler.
- Adult, Aged, Disease Progression, Female, Humans, Male, Middle Aged, Observer Variation, Prospective Studies, Sensitivity and Specificity.
Abstract
Objective. Our prospective study aimed to demonstrate that the cumulative synovial power Doppler (PD) ultrasound scores correlate with radiographic progression better than conventional measures in patients with rheumatoid arthritis (RA). We also investigated the difference between antirheumatic agents. Methods. Sixty-nine patients with RA who had recently received either methotrexate (MTX; n= 23), tumor necrosis factor (TNF) antagonists (n= 28), or tocilizumab (TCZ; n= 18) were enrolled. Patients underwent clinical, laboratory, and ultrasonographic assessment at baseline, 12 weeks, and 24 weeks. Radiographic damage was evaluated using van der Heijde modified total Sharp score (TSS) at baseline and 24 weeks. Results. Fifty-seven patients continued the same treatment regimen for 24 weeks and completed the study, and 21 patients (36.8%) showed radiographic progression during the study period. In all patients, ΔTSS significantly correlated both with cumulative 28-joint Disease Activity Score-C-reactive protein (DAS28-CRP; p= 0.342, p=0.009) and cumulative total PD scores (p= 0.357, p= 0.006). In MTX-treated patients, cumulative total PD scores significantly correlated with ΔTSS (p= 0.679, p= 0.004), whereas cumulative DAS28-CRP did not (p= 0.487, p= 0.056). However, cumulative total PD scores did not correlate with ΔTSS in TNF antagonist-treated or TCZ-treated patients. Conclusion. Our data confirm the evidence that synovial PD activity more accurately reflects active synovial inflammation (which actually causes joint destruction) than do conventional measures in patients treated with MTX. Our data also indicate that TNF antagonists can inhibit short-term radiographic progression in the presence of active synovitis.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000032
- to stream PascalFrancis, to step Curation: 000232
- to stream PascalFrancis, to step Checkpoint: 000057
- to stream Main, to step Merge: 003419
- to stream PubMed, to step Corpus: 001560
- to stream PubMed, to step Curation: 001560
- to stream PubMed, to step Checkpoint: 001604
- to stream Ncbi, to step Merge: 000935
- to stream Ncbi, to step Curation: 000935
- to stream Ncbi, to step Checkpoint: 000935
- to stream Main, to step Merge: 002809
- to stream Main, to step Curation: 003398
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Correlation of Radiographic Progression with the Cumulative Activity of Synovitis Estimated by Power Doppler Ultrasound in Rheumatoid Arthritis: Difference Between Patients Treated with Methotrexate and Those Treated with Biological Agents</title><author><name sortKey="Ikeda, Kei" sort="Ikeda, Kei" uniqKey="Ikeda K" first="Kei" last="Ikeda">Kei Ikeda</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Nakagomi, Daiki" sort="Nakagomi, Daiki" uniqKey="Nakagomi D" first="Daiki" last="Nakagomi">Daiki Nakagomi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Sanayama, Yoshie" sort="Sanayama, Yoshie" uniqKey="Sanayama Y" first="Yoshie" last="Sanayama">Yoshie Sanayama</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Yamagata, Mieko" sort="Yamagata, Mieko" uniqKey="Yamagata M" first="Mieko" last="Yamagata">Mieko Yamagata</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Okubo, Ayako" sort="Okubo, Ayako" uniqKey="Okubo A" first="Ayako" last="Okubo">Ayako Okubo</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Iwamoto, Taro" sort="Iwamoto, Taro" uniqKey="Iwamoto T" first="Taro" last="Iwamoto">Taro Iwamoto</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Kawashima, Hirotoshi" sort="Kawashima, Hirotoshi" uniqKey="Kawashima H" first="Hirotoshi" last="Kawashima">Hirotoshi Kawashima</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Takahashi, Kentaro" sort="Takahashi, Kentaro" uniqKey="Takahashi K" first="Kentaro" last="Takahashi">Kentaro Takahashi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Nakajima, Hiroshi" sort="Nakajima, Hiroshi" uniqKey="Nakajima H" first="Hiroshi" last="Nakajima">Hiroshi Nakajima</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0028355</idno><date when="2013">2013</date><idno type="stanalyst">PASCAL 14-0028355 INIST</idno><idno type="RBID">Pascal:14-0028355</idno><idno type="wicri:Area/PascalFrancis/Corpus">000032</idno><idno type="wicri:Area/PascalFrancis/Curation">000232</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000057</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000057</idno><idno type="wicri:doubleKey">0315-162X:2013:Ikeda K:correlation:of:radiographic</idno><idno type="wicri:Area/Main/Merge">003419</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:24187096</idno><idno type="wicri:Area/PubMed/Corpus">001560</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001560</idno><idno type="wicri:Area/PubMed/Curation">001560</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001560</idno><idno type="wicri:Area/PubMed/Checkpoint">001604</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001604</idno><idno type="wicri:Area/Ncbi/Merge">000935</idno><idno type="wicri:Area/Ncbi/Curation">000935</idno><idno type="wicri:Area/Ncbi/Checkpoint">000935</idno><idno type="wicri:doubleKey">0315-162X:2013:Ikeda K:correlation:of:radiographic</idno><idno type="wicri:Area/Main/Merge">002809</idno><idno type="wicri:Area/Main/Curation">003398</idno><idno type="wicri:Area/Main/Exploration">003398</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Correlation of Radiographic Progression with the Cumulative Activity of Synovitis Estimated by Power Doppler Ultrasound in Rheumatoid Arthritis: Difference Between Patients Treated with Methotrexate and Those Treated with Biological Agents</title><author><name sortKey="Ikeda, Kei" sort="Ikeda, Kei" uniqKey="Ikeda K" first="Kei" last="Ikeda">Kei Ikeda</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Nakagomi, Daiki" sort="Nakagomi, Daiki" uniqKey="Nakagomi D" first="Daiki" last="Nakagomi">Daiki Nakagomi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Sanayama, Yoshie" sort="Sanayama, Yoshie" uniqKey="Sanayama Y" first="Yoshie" last="Sanayama">Yoshie Sanayama</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Yamagata, Mieko" sort="Yamagata, Mieko" uniqKey="Yamagata M" first="Mieko" last="Yamagata">Mieko Yamagata</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Okubo, Ayako" sort="Okubo, Ayako" uniqKey="Okubo A" first="Ayako" last="Okubo">Ayako Okubo</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Iwamoto, Taro" sort="Iwamoto, Taro" uniqKey="Iwamoto T" first="Taro" last="Iwamoto">Taro Iwamoto</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Kawashima, Hirotoshi" sort="Kawashima, Hirotoshi" uniqKey="Kawashima H" first="Hirotoshi" last="Kawashima">Hirotoshi Kawashima</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Takahashi, Kentaro" sort="Takahashi, Kentaro" uniqKey="Takahashi K" first="Kentaro" last="Takahashi">Kentaro Takahashi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Nakajima, Hiroshi" sort="Nakajima, Hiroshi" uniqKey="Nakajima H" first="Hiroshi" last="Nakajima">Hiroshi Nakajima</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Journal of rheumatology</title><title level="j" type="abbreviated">J. rheumatol.</title><idno type="ISSN">0315-162X</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of rheumatology</title><title level="j" type="abbreviated">J. rheumatol.</title><idno type="ISSN">0315-162X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adalimumab</term><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antineoplastic agent</term><term>Antirheumatic Agents (therapeutic use)</term><term>Antirheumatic agent</term><term>Arthritis, Rheumatoid (diagnostic imaging)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Arthrography (methods)</term><term>Arthrography (statistics & numerical data)</term><term>Biological agent</term><term>Chronic</term><term>Disease Progression</term><term>Doppler ultrasound study</term><term>Echography</term><term>Etanercept</term><term>Evolution</term><term>Female</term><term>Human</term><term>Humans</term><term>Immunoglobulin G (therapeutic use)</term><term>Infliximab</term><term>Male</term><term>Methotrexate</term><term>Methotrexate (therapeutic use)</term><term>Middle Aged</term><term>Observer Variation</term><term>Prognosis</term><term>Prospective Studies</term><term>Radiography</term><term>Receptors, Tumor Necrosis Factor (therapeutic use)</term><term>Rheumatoid arthritis</term><term>Rheumatology</term><term>Sensitivity and Specificity</term><term>Synovitis</term><term>Synovitis (diagnostic imaging)</term><term>Synovitis (drug therapy)</term><term>Treatment</term><term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term><term>Ultrasonography, Doppler (methods)</term><term>Ultrasonography, Doppler (statistics & numerical data)</term><term>Ultrasound</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adalimumab</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Arthrographie ()</term><term>Biais de l'observateur</term><term>Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs)</term><term>Femelle</term><term>Humains</term><term>Immunoglobuline G (usage thérapeutique)</term><term>Infliximab</term><term>Mâle</term><term>Méthotrexate (usage thérapeutique)</term><term>Polyarthrite rhumatoïde (imagerie diagnostique)</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Récepteurs aux facteurs de nécrose tumorale (usage thérapeutique)</term><term>Sensibilité et spécificité</term><term>Sujet âgé</term><term>Synovite (imagerie diagnostique)</term><term>Synovite (traitement médicamenteux)</term><term>Échographie-doppler ()</term><term>Étanercept</term><term>Études prospectives</term><term>Évolution de la maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Immunoglobulin G</term><term>Methotrexate</term><term>Receptors, Tumor Necrosis Factor</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adalimumab</term><term>Etanercept</term><term>Infliximab</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>Synovitis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>Synovitis</term></keywords><keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Polyarthrite rhumatoïde</term><term>Synovite</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Arthrography</term><term>Ultrasonography, Doppler</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Arthrography</term><term>Ultrasonography, Doppler</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term><term>Synovite</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Anticorps monoclonaux humanisés</term><term>Antirhumatismaux</term><term>Immunoglobuline G</term><term>Méthotrexate</term><term>Récepteurs aux facteurs de nécrose tumorale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Observer Variation</term><term>Prospective Studies</term><term>Sensitivity and Specificity</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Adalimumab</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Arthrographie</term><term>Biais de l'observateur</term><term>Femelle</term><term>Humains</term><term>Infliximab</term><term>Mâle</term><term>Polyarthrite rhumatoïde</term><term>Radiographie</term><term>Evolution</term><term>Pronostic</term><term>Sensibilité et spécificité</term><term>Sujet âgé</term><term>Synovite</term><term>Dopplérométrie</term><term>Ultrason</term><term>Homme</term><term>Traitement</term><term>Méthotrexate</term><term>Agent biologique</term><term>Echographie</term><term>Rhumatologie</term><term>Chronique</term><term>Antirhumatismal</term><term>Anticancéreux</term><term>Échographie-doppler</term><term>Étanercept</term><term>Études prospectives</term><term>Évolution de la maladie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective. Our prospective study aimed to demonstrate that the cumulative synovial power Doppler (PD) ultrasound scores correlate with radiographic progression better than conventional measures in patients with rheumatoid arthritis (RA). We also investigated the difference between antirheumatic agents. Methods. Sixty-nine patients with RA who had recently received either methotrexate (MTX; n= 23), tumor necrosis factor (TNF) antagonists (n= 28), or tocilizumab (TCZ; n= 18) were enrolled. Patients underwent clinical, laboratory, and ultrasonographic assessment at baseline, 12 weeks, and 24 weeks. Radiographic damage was evaluated using van der Heijde modified total Sharp score (TSS) at baseline and 24 weeks. Results. Fifty-seven patients continued the same treatment regimen for 24 weeks and completed the study, and 21 patients (36.8%) showed radiographic progression during the study period. In all patients, ΔTSS significantly correlated both with cumulative 28-joint Disease Activity Score-C-reactive protein (DAS28-CRP; p= 0.342, p=0.009) and cumulative total PD scores (p= 0.357, p= 0.006). In MTX-treated patients, cumulative total PD scores significantly correlated with ΔTSS (p= 0.679, p= 0.004), whereas cumulative DAS28-CRP did not (p= 0.487, p= 0.056). However, cumulative total PD scores did not correlate with ΔTSS in TNF antagonist-treated or TCZ-treated patients. Conclusion. Our data confirm the evidence that synovial PD activity more accurately reflects active synovial inflammation (which actually causes joint destruction) than do conventional measures in patients treated with MTX. Our data also indicate that TNF antagonists can inhibit short-term radiographic progression in the presence of active synovitis.</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Ikeda, Kei" sort="Ikeda, Kei" uniqKey="Ikeda K" first="Kei" last="Ikeda">Kei Ikeda</name></noRegion><name sortKey="Iwamoto, Taro" sort="Iwamoto, Taro" uniqKey="Iwamoto T" first="Taro" last="Iwamoto">Taro Iwamoto</name><name sortKey="Kawashima, Hirotoshi" sort="Kawashima, Hirotoshi" uniqKey="Kawashima H" first="Hirotoshi" last="Kawashima">Hirotoshi Kawashima</name><name sortKey="Nakagomi, Daiki" sort="Nakagomi, Daiki" uniqKey="Nakagomi D" first="Daiki" last="Nakagomi">Daiki Nakagomi</name><name sortKey="Nakajima, Hiroshi" sort="Nakajima, Hiroshi" uniqKey="Nakajima H" first="Hiroshi" last="Nakajima">Hiroshi Nakajima</name><name sortKey="Okubo, Ayako" sort="Okubo, Ayako" uniqKey="Okubo A" first="Ayako" last="Okubo">Ayako Okubo</name><name sortKey="Sanayama, Yoshie" sort="Sanayama, Yoshie" uniqKey="Sanayama Y" first="Yoshie" last="Sanayama">Yoshie Sanayama</name><name sortKey="Takahashi, Kentaro" sort="Takahashi, Kentaro" uniqKey="Takahashi K" first="Kentaro" last="Takahashi">Kentaro Takahashi</name><name sortKey="Yamagata, Mieko" sort="Yamagata, Mieko" uniqKey="Yamagata M" first="Mieko" last="Yamagata">Mieko Yamagata</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003398 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003398 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:14-0028355
|texte= Correlation of Radiographic Progression with the Cumulative Activity of Synovitis Estimated by Power Doppler Ultrasound in Rheumatoid Arthritis: Difference Between Patients Treated with Methotrexate and Those Treated with Biological Agents
}}
| This area was generated with Dilib version V0.6.34. |  |